Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity.

Alzheimers Dement · 2025 · PMC12122256 · PMID 40442871

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0990

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

However, only the rapid decline group exhibited a significantly steeper increase than the stable group ( b = 0.262, SE = 0.11, p < 0.05), whereas the slow decline group showed a trend‐level significance ( b = 0.192, SE = 0.10, p = 0.06). 4 DISCUSSION In this study, we assessed the heterogeneity of clinical progression in Aβ+ cognitively normal and MCI individuals across two independent cohorts.

also in 53,322 other papers

did not reach statistical significancep = 0.099so close (0.05 < p ≤ 0.1)

Within the rapid cognitive decline cluster, MCI cases exhibited higher mean plasma p‐tau217 levels than CN/SCD cases; however, this difference did not reach statistical significance ( p = 0.099), and the CN/SCD subgroup was small ( n = 9), likely limiting the reliability of this comparison.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.